Making an Impact on Movement Disorders
AI applications for improving treatment for patients with movement disorders includes work by assistant professor Coralie de Hemptinne, PhD, MS, and biomedical scientist Jackson Cagle, PhD, researchers at the Norman Fixel Institute for Neurological Diseases at UF Health who have developed an algorithm to optimize deep brain stimulation, or DBS, a treatment that involves placing a thin wire in the brain in areas that control movement. Their technology, which received UF Innovate’s 2022 Invention of the Year award, predicts the best stimulation settings based on individual brain activity, shortening the wait to see improvement in symptoms.
Clinical Spotlight: UF Health Aortic Disease Center Celebrates Five Years
As of 2023, the team at UF Health's Aortic Disease Center has surpassed their 2018 goals of increasing case volume, broadening research, and improving the quality of treatment for patients. Led by Tom Martin, M.D., the center is also leveraging AI to improve the future of health care and put patients first.
Tech Tuesday: A Helpful Virus
In this week's Tech Tuesday for WCJB TV20, UF Innovate's Melanie Morón interviews Dr. Arun Srivastava from the University of Florida's College of Medicine Department of Pediatrics who introduces us to a virus -- the adeno-associated virus or AAV -- that cures rather than infects. AAV has cured nine human diseases. The FDA has approved five drugs using it. And Dr. Srivastava's lab of scientists is working to make the vectors more efficient.
Can Milk Cure COVID-19? Not Exactly, but a New Treatment Shows Promise
College of Medicine researcher Dr. David Ostrov wrote this opinion piece for The Hill after his discovery of a potential therapy or preventative for COVID became public knowledge:
“Got milk? Cure COVID” was a meme that started circulating after one of our discoveries from the University of Florida went public. It playfully highlighted a major medical milestone: We had found a combination of two over-the-counter products that could inhibit 99 percent of SARS-CoV-2 replication in human lung cells, and one of them was milk-based.
Discovery Shows How Pervasive Epstein-Barr Virus Could Be Thwarted
New, early findings by University of Florida Health researchers show how the Epstein-Barr virus’s advance could be thwarted.
BioMérieux Receives CE Mark for Biomarker Assay for Mild TBI
BioMérieux, which signed an agreement in 2017 with Banyan Biomarkers to commercialize its TBI assay, has obtained the CE Mark for its assay to detect two biomarkers associated with mild traumatic brain injury (mTBI).
Capsida Biotherapeutics Enters Strategic Collaboration With Kate Therapeutics to Manufacture KateTx’s Next-Generation Gene Therapies
Capsida Biotherapeutics Inc. and UF startup Kate Therapeutics announced a strategic partnership to leverage Capsida's expertise and adeno-associated virus (AAV) manufacturing capabilities to enable KateTx's initial internal portfolio of muscle and heart disease programs.
Atsena Therapeutics Doses First Patient in Phase I/II Clinical Trial of ATSN-201 for Treatment of X-Linked Retinoschisis
Atsena Therapeutics announced the first patient has been dosed in its Phase I/II clinical trial, the LIGHTHOUSE study, evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS).
National Cade Prize for Innovation Names 21 Finalists
Judges for 2023’s National Cade Prize for Innovation named this year’s 21 Fibonacci Finalists. Finalists will compete to win $10,000 in their respective category group—Agriculture and Environmental, Healthcare/Biomedical, IT/Tech, Energy, and Wildcard. One of the five category winners will be selected as the Inventivity™ Grand Prize winner and take home an additional $50,000 prize. Two UF startups -- Lactovid and Analyz -- are listed among the Fibonacci Finalists.
Atsena Therapeutics Receives FDA Clearance of an Investigational Gene Therapy for X-Linked Retinoschisis
The U.S. Food and Drug Administration (FDA) has cleared Atsena Therapeutics' Investigational New Drug (IND) application for a Phase I/II clinical trial of ATSN-201 in patients with X-linked retinoschisis (XLRS). Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness.
